Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome

Annals of Pharmacotherapy

Volumn 45, Issue 11, 2011, Pages 1462-

  Musselman, Megan E ^a   Browning, Linda A ^b   Parker Jr , Dennis ^c   Saely, Suprat ^b  

^a INDIANA UNIVERSITY HEALTH   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Antipsychotics; Clozapine; Neuroleptic malignant syndrome; Olanzapine; Prochlorperazine; Schizophrenia

Indexed keywords

AMMONIA; BROMOCRIPTINE; CARBAMAZEPINE; CLOZAPINE; CREATINE KINASE; CREATININE; LACTULOSE; LORAZEPAM; OLANZAPINE; OXCARBAZEPINE; PARACETAMOL; POTASSIUM; PROCHLORPERAZINE; SODIUM; SODIUM CHLORIDE;

ADULT; AGITATION; AMMONIA BLOOD LEVEL; ARTICLE; BATTERING; CASE REPORT; COOLING; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIAPHORESIS; DRUG WITHDRAWAL; EMERGENCY WARD; FEVER; FLUID RESUSCITATION; HEART RATE; HOSPITAL ADMISSION; HUMAN; HYPERTHERMIA; HYPOKALEMIA; IMPULSIVENESS; LEUKOCYTE COUNT; MALE; MENTAL HEALTH CENTER; MUSCLE RIGIDITY; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE; TACHYCARDIA; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 80155167173     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1BR11K     Document Type: Article

References (20)

1. Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses]. Ann Med Psychol (Paris) 1960;118:145-52.
2. Adityanjee, Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol 1999;22:151-8.
3. Keck PE Jr, Pope HG Jr, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991; 148:880-2.
4. Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004;37:S54-64.
5. Srivastava A, Borkar HA, Chandak S. Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia. Psychiatry Clin Neurosci 2009;63:119-21.
6. Kunz M, Gomes FA, Tramontina JF, Kapczinski F. Late-onset neuroleptic malignant syndrome in a patient using olanzapine. J Clin Psychopharmacol 2007;27:303-4.
7. Stanfield SC, Privette T. Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. J Emerg Med 2000;19:355-7.
8. Filice GA, McDougall BC, Ercan-Fang N, Billington CJ. Neuroleptic malignant syndrome associated with olanzapine. Ann Pharmacother 1998;32:1158-9. DOI 10.1345/aph.18151
9. Pesola GR, Quinto C. Prochlorperazine-induced neuroleptic malignant syndrome. J Emerg Med 1996;14:727-9.
10. Manser TJ, Warner JF. Neuroleptic malignant syndrome associated with prochlorperazine. South Med J 1990;83:73-4.
11. Nonino F, Campomori A. Neuroleptic malignant syndrome associated with metoclopramide (letter). Ann Pharmacother 1999;33:644-5. DOI 10.1345/aph.18256
12. Bakri YN, Khan R, Subhi J, Kawi Z. Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. Gynecol Oncol 1992;44:189-90.
13. Nachreiner R, Balledux J, Zieger M, Viegas O, Sood R. Neuroleptic malignant syndrome associated with metoclopramide in a burn patient. J Burn Care Res 2006;27:237-41.
14. Mendhekar DN, Andrade CR. Neuroleptic malignant syndrome with promethazine. Aust N Z J Psychiatry 2005;39:310. DOI 10.1111/j.1440-1614.2005.01568.x
15. Chan-Tack KM. Neuroleptic malignant syndrome due to promethazine. South Med J 1999;92:1017-8.
16. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
17. Caroff SN, Campbell EC, Sullivan KA. Neuroleptic malignant syndrome in elderly patients. Expert Rev Neurother 2007;7:423-31.
18. McAllen KJ, Schwartz DR. Adverse drug reactions resulting in hyperthermia in the intensive care unit. Crit Care Med 2010;38:S244-52.
19. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-70.
20. Gheorghiu S, Knobler HY, Drumer D. Recurrence of neuroleptic malignant syndrome with olanzapine treatment. Am J Psychiatry 1999;156:1836.